Allarity Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement

Benzinga10/10 20:13

Allarity Therapeutics Strengthens Leadership With Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

GlobeNewswire10/03 20:00

Allarity Therapeutics Has Received A Decision To Grant European Patent Number EP3794149 Titled "METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS".

Benzinga09/27 03:59

Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Benzinga09/17 17:48

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment With Stenoparib in Advanced Ovarian Cancer Trial

GlobeNewswire09/16 20:00

Allarity Therapeutics Shares Are Trading Higher. The Company Appointed a New CFO.

Benzinga09/14 02:07